Preventive cardiologyEfficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease†
Section snippets
Methods
This study (Protocol 079) was a 6-week, multicenter, double-blind, randomized, parallel-group titration study in patients with hypercholesterolemia conducted in 72 sites in the United States (65 sites), Canada (4 sites), Austria (2 sites), and Costa Rica (1 site) from February 13, 2006, to January 17, 2008. The protocol was approved by appropriate institutional review boards, and all patients provided informed written consent.
Patients meeting the inclusion criteria were men and women aged 18 to
Results
The flow of participants through the study is summarized in Figure 1. There were generally no clinically meaningful differences in the distribution of baseline characteristics between treatment groups, including demographics, risk factors, and lipid values and ratios (Table 1, Table 2). Baseline demographics revealed that 60% of the patients were white, 26% multiracial (Hispanic or Latino), 55% men, and 74% aged <65 years.
The coadministration of ezetimibe 10 mg with atorvastatin 20 mg produced
Discussion
The primary objective of this study was to compare the LDL cholesterol–lowering efficacy of ezetimibe 10 mg added to atorvastatin 20 mg with that of the doubling of atorvastatin to 40 mg in patients with hypercholesterolemia at moderately high risk for coronary heart disease who had LDL cholesterol levels ≥100 mg/dl while taking atorvastatin 20 mg. In this study, the coadministration of ezetimibe with atorvastatin 20 mg resulted in significantly greater reductions in LDL cholesterol and better
Acknowledgments
We wish to thank Mary E. Hanson, PhD, of Merck & Company for critical review and Martha Vollmer, MA, of Merck & Company for editorial assistance on this report, although neither met all criteria for authorship.
References (14)
- et al.
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
J Am Coll Cardiol
(2004) - et al.
Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial
Mayo Clin Proc
(2004) - et al.
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia
Am J Cardiol
(2004) - et al.
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin
Am Heart J
(2004) - et al.
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe
Curr Med Res Opin
(2006) - et al.
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial
Circulation
(2003) - et al.
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia
Int J Clin Pract
(2004)
Cited by (0)
This study was supported by Merck/Schering-Plough Pharmaceuticals, North Wales, Pennsylvania.
- †
Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.